Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Janis Taube

Dermatopathology Baltimore, MD Medical Doctor

NPI 1629121801 CMS profile 921890

600 N Wolfe St, Dept. Pathology, Rm 401 Carnegie, Baltimore, MD 21287

Open in the dashboard

General payments

$225,260

156 records reported · program years 2019–2025

Research payments

$3,228

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Janis Taube of Baltimore, MD is reported in the CMS Open Payments database as having received $225,260 across 156 general payments and $3,228 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Dermatopathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $81,460 55
2025 Research $702 3
2024 General $39,323 37
2023 General $1,353 6
2023 Research $400 2
2022 General $39,137 12
2022 Research $2,126 4
2021 General $5,000 3
2020 General $29,464 20
2019 General $29,523 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janis Taube
  • Dermatopathology median
  • Middle half of Dermatopathology
  • National median

In program year 2025, general payments to Janis Taube were reported at $81,460. Among 238 Dermatopathology profiles paid that year, the median was $251 and the middle half received between $93 and $1,140.

Show as a table
Year Janis Taube Dermatopathology median Middle half National median
2019 $29,523 $295 $101–$807 $163
2020 $29,464 $154 $53–$443 $114
2021 $5,000 $226 $66–$781 $132
2022 $39,137 $258 $76–$906 $149
2023 $1,353 $303 $93–$1,129 $160
2024 $39,323 $324 $101–$1,343 $164
2025 $81,460 $251 $93–$1,140 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $136,641 85 payments
  2. AstraZeneca UK Limited $34,018 11 payments
  3. E.R. Squibb & Sons, L.L.C. $21,835 20 payments
  4. Regeneron Pharmaceuticals, Inc. $21,278 24 payments
  5. Ventana Medical Systems, Inc. $4,648 9 payments
  6. Moderna TX, Inc. $3,750 1 payment
  7. Genentech, Inc. $2,195 2 payments
  8. GlaxoSmithKline, LLC. $800 1 payment
  9. Bristol-Myers Squibb Company $59 2 payments
  10. Eli Lilly and Company $37 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $148,238 45 payments
  2. Travel and Lodging $60,636 57 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,226 5 payments
  4. Food and Beverage $2,724 48 payments
  5. Education $436 1 payment
Products named General payments · program years 2019–2025
  1. KEYTRUDA $50,425 32 payments
  2. IMFINZI $26,375 9 payments
  3. LIBTAYO $21,278 24 payments
  4. VENTANA RESEARCH & DEVELOPMENT $3,148 8 payments
  5. TECENTRIQ $1,695 1 payment
  6. OPDIVO $1,569 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $3,228 9 payments

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$5,625

Medicare's payments for the services billed

Medicare patients

129

Average age 73

Services billed

218

61 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 34%
Diabetes 33%
Chronic kidney disease 33%
Heart failure 30%
Depression 25%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LIBTAYO
  • Regeneron Pharmaceuticals, Inc. $15,270
$15,270 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $618
$618 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatopathology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record